YONKERS, N.Y., April 8 /PRNewswire-FirstCall/ -- Advanced Viral Research
Corp. (OTC Bulletin Board: ADVR) announced today that Carol Epstein, MD has
been appointed Acting Medical Director for the Company. Dr. Epstein is the
co-founder of MediVector, Inc., a biopharmaceutical consulting firm with
proprietary technology that can enable companies to cut the time and cost of
drug development.
"I am extremely pleased that Dr. Epstein has joined our team. Carol is
known for her creative and strategic thinking," said Elma S. Hawkins, PhD,
MBA, President and CEO of Advanced Viral Research Corp. "With her wealth of
knowledge and expertise in clinical research and drug development, Carol is
uniquely qualified to assist us in translating AVR118 into commercial
realization. This marks the first time we have had someone with Dr. Epstein's
level of expertise in clinical development at ADVR and demonstrates our
commitment and focus in this area."
Dr. Epstein started her career in the pharmaceutical industry in 1983 with
Ayerst, a division of American Home Products. She then joined Immunex where
she built the clinical group and was responsible for the successful clinical
strategy that led to the approval of GM-CSF. Dr. Epstein later became Chief
Medical Officer of Immunogen, and then co-founded BioLogics Services, Inc, a
biopharmaceutical consulting firm. She has had extensive experience in
oncology, immunology and autoimmune diseases, wound healing, cardiology,
endocrinology and metabolism, and transplantation. Dr. Epstein graduated from
MIT and Yale University School of Medicine.
"I look forward to working with ADVR in developing and executing a
comprehensive strategic plan for the clinical development of this very
interesting and promising product," said Dr. Epstein.
Advanced Viral Research Corp., based in Yonkers, New York, is a
biopharmaceutical firm dedicated to improving patients' lives by researching,
developing and bringing to market new and effective therapies for viral and
other diseases. ADVR's lead product, AVR118 (formerly known as Product R),
represents a biopolymer that possesses novel immunomodulator activity. This
peptide-nucleic acid, which to date has shown a very favorable safety profile,
appears to stimulate the proinflammatory responses required to combat viral
infections such as AIDS and human papilloma virus and to dampen aberrant
autoimmune-type inflammatory responses, such as occur in patients with
rheumatoid arthritis. AVR118 is in clinical trials in Israel for the
treatment of cachexia (body wasting) in patients with AIDS.
For further information regarding Advanced Viral Research Corp., please
visit our website at http://www.adviral.com.
Note: This news release contains forward-looking statements that involve
risks associated with clinical development, regulatory approvals, including
application to the FDA, product commercialization and other risks described
from time to time in the SEC reports filed by the Company. AVR118 (Product R)
is not approved by the U.S. Food and Drug Administration or any comparable
agencies of any other countries. There is no assurance that the Company will
be able to secure the financing necessary to continue and/or complete the
clinical trials of AVR118 or satisfy certain other conditions relating to
clinical trials including obtaining adequate insurance on terms acceptable to
the Company or that if completed, clinical trials performed outside the United
States will assist the Company in obtaining FDA or other regulatory approval.
The Company undertakes no obligation to update or revise the information
contained in this announcement whether as a result of new information, future
events or circumstances or otherwise.
Contact: Ronnie Welch or Kelly Cinelli
CWR & Partners
508/222-4802
SOURCE Advanced Viral Research Corp.
 back to top
Related links:
http://www.adviral.com
Company News On-Call:
http://www.prnewswire.com/comp/903002.html
CONTACT:
Ronnie Welch or Kelly Cinelli, both of CWR &
Partners, +1-508-222-4802, for Advanced Viral Research Corp.
|
